Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

Clinical trial NCT05154994 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05154994
Sponsor: University of Utah
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Infiltrating Urothelial Carcinoma, Sarcomatoid Variant Locally Advanced Urothelial Carcinoma Metastatic Urothelial Carcinoma Unresectable Urothelial Carcinoma

Start date: 2022-01-14
Primary completion: 2026-08-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.